Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetic Autonomic Neuropathy Clear all
Completed Phase 2 Interventional

A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain

NCT01345045
View directory record Official record
Conditions
Diabetic Neuropathic Pain
Interventions
ABT-639, pregabalin, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Little Rock, Arkansas • Anaheim, California • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Jul 23, 2026, 11:49 AM EDT
Completed Phase 4 Interventional

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

NCT00904202
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Complex Regional Pain Syndrome, Carpal Tunnel Syndrome, HIV Neuropathy, Idiopathic Sensory Neuropathy, Peripheral Neuropathy
Interventions
Placebo Capsules + Placebo Patch, Placebo capsules + Lidoderm®, Gabapentin + Placebo, Gabapentin + Lidoderm®, Gabapentin 300 mg capsules 1800 mg/day + placebo patch, Gabapentin 1800 mg/day + Lidoderm patch
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
7
States / cities
Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Jul 23, 2026, 11:49 AM EDT
Completed Phase 4 Interventional Results available

Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects

NCT02682901
View directory record Official record
Conditions
Diabetic Autonomic Neuropathy
Interventions
Cycloset, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
30 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Jul 23, 2026, 11:49 AM EDT
Completed Phase 3 Interventional

Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT)

NCT00594152
View directory record Official record
Conditions
Diabetic Nephropathy, Diabetic Retinopathy
Interventions
CIIIT
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1995
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Jul 23, 2026, 11:49 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time

NCT01223365
View directory record Official record
Conditions
Chronic Pain
Interventions
Hydrocodone ER
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
54
States / cities
Mobile, Alabama • Anaheim, California • Beverly Hills, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Jul 23, 2026, 11:49 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

NCT00343733
View directory record Official record
Conditions
Pain
Interventions
OraVescent Fentanyl
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
21
States / cities
Hot Springs, Arkansas • Los Gatos, California • Oxnard, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jul 23, 2026, 11:49 AM EDT
Completed Phase 3 Interventional Results available

An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes

NCT00116207
View directory record Official record
Conditions
Diabetic Autonomic Neuropathy
Interventions
ORAL ANTIOXIDANT
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Jul 23, 2026, 11:49 AM EDT
Completed No phase listed Observational

Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project

NCT07005947
View directory record Official record
Conditions
Long COVID-19, Acute COVID-19, Postural Orthostatic Tachycardia Syndrome (POTS), Diabetic Neuropathy
Interventions
Not listed
Lead sponsor
CND Life Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 11:49 AM EDT
Completed No phase listed Observational

The Relative Prevalence and Severity of Autonomic Nervous System Dysfunction

NCT00919347
View directory record Official record
Conditions
Cardiovascular Autonomic Neuropathy, Diabetic Autonomic Neuropathy, Autonomic Dysfunction
Interventions
ANSAR ANX 3.0 Software
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Jul 23, 2026, 11:49 AM EDT
Recruiting Not applicable Interventional

Neurologic Stem Cell Treatment Study

NCT02795052
View directory record Official record
Conditions
Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Interventions
Intravenous and Intranasal BMSC
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 11:49 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

NCT00738062
View directory record Official record
Conditions
Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
44
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Jul 23, 2026, 11:49 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

NCT00633880
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Interventions
Placebo, Droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
44
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Jul 23, 2026, 11:49 AM EDT
Completed Not applicable Interventional

Improving Autonomic Function and Balance in Diabetic Neuropathy

NCT01864460
View directory record Official record
Conditions
Diabetes, Neuropathy, Impaired Glucose Tolerance
Interventions
lifestyle modification
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
30 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 23, 2026, 11:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Autonomic Nervous System Dysfunction and Peripheral Neuropathy in a Cohort of Asymptomatic Juvenile Diabetic Patients (Type I): A Case-Controlled Study

NCT00466778
View directory record Official record
Conditions
Peripheral Neuropathy, Autonomic Neuropathy
Interventions
Not listed
Lead sponsor
Weintraub, Michael I., MD, FACP, FAAN
Individual
Eligibility
10 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Briarcliff Manor, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2007 · Synced Jul 23, 2026, 11:49 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Exenatide in Patients With Diabetic Neuropathy

NCT00855439
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetic Peripheral Neuropathy
Interventions
Exenatide, Glargine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Jul 23, 2026, 11:49 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa

NCT00782340
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Interventions
Placebo, Droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Jul 23, 2026, 11:49 AM EDT
Terminated Not applicable Interventional

Enhance Balance and Mobility in People With Type 2 Diabetic Peripheral Neuropathy

NCT02541838
View directory record Official record
Conditions
Diabetes Complications, Diabetic Neuropathies
Interventions
Muscle power, balance perturbation, aerobic exercise
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
55 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Jul 23, 2026, 11:49 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy

NCT00760955
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
TAK-583, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
33
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Jul 23, 2026, 11:49 AM EDT
Terminated Phase 4 Interventional Results available

Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy

NCT00619983
View directory record Official record
Conditions
Diabetic Neuropathic Pain, Chronic Low Back Pain
Interventions
donepezil, duloxetine, donepezil 2.5 mg and duloxetine 30mg, placebo, gabapentin
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Jul 23, 2026, 11:49 AM EDT
Not listed Phase 2 Interventional

The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes

NCT03426085
View directory record Official record
Conditions
Autonomic Nervous System Diseases, Sweat Gland Diseases, Diabetic Neuropathy With Neurologic Complication
Interventions
Liraglutide 6 mg Solution for Injection, Placebo
Drug · Other
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2019 · Synced Jul 23, 2026, 11:49 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

NCT00580294
View directory record Official record
Conditions
Pain
Interventions
Oxymorphone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Jul 23, 2026, 11:49 AM EDT